Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Myofibroblasts produce the fibrous scar in hepatic fibrosis. In the carbon tetrachloride (CCl(4)) model of liver fibrosis, quiescent hepatic stellate cells (HSC) are activated to become myofibroblasts. When the underlying etiological agent is removed, clinical and experimental fibrosis undergoes a remarkable regression with complete disappearance of these myofibroblasts. Although some myofibroblasts apoptose, it is unknown whether other myofibroblasts may revert to an inactive phenotype during regression of fibrosis. We elucidated the fate of HSCs/myofibroblasts during recovery from CCl(4)- and alcohol-induced liver fibrosis using Cre-LoxP-based genetic labeling of myofibroblasts. Here we demonstrate that half of the myofibroblasts escape apoptosis during regression of liver fibrosis, down-regulate fibrogenic genes, and acquire a phenotype similar to, but distinct from, quiescent HSCs in their ability to more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and strongly contribute to liver fibrosis. Inactivation of HSCs was associated with up-regulation of the anti-apoptotic genes Hspa1a/b, which participate in the survival of HSCs in culture and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, restored RSPO3 expression during HSC deactivation52,53 or by therapeutic interventions might help to regain hepatocyte functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [52]
In the citing paper
“Animal models reinforce the capacity of the injured liver to regress fibrosis and provide important platform for dissecting underlying mechanisms, although it should be noted that fibrosis in mice regresses incredibly rapidly, which may be in part attributed to the short duration of models (weeks to months in mice vs. years to decades in humans) and initiation of fibrosis at relatively young age (”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [262]
In the citing paper
“Fibroblast activation also involves increased activity of key glycolytic enzymes, such as hexokinase 2 and lactate dehydrogenase (LDH)47, which in turn increase cell proliferation47 and collagen synthesis48.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
In the citing paper
“During enhanced glycolysis, increased amounts of pyruvate are converted to acetyl-CoA in the mitochondrial matrix47 before entering the citric acid cycle. This yields intermediate metabolites, such as succinate, which promote fibrosis49.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [47]
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Self-citationSenescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationBataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075 · cited 8×
“Myofibroblasts are aSMA collagen type I cells that are absent from the normal uninjured liver, rapidly emerge infibrotic liver to produce thefibrous scar, and completely disappear with regression of liver fibrosis (1, 2).”
BackgroundInfluentialThe role of matrix stiffness in regulating cell behavior†
Wells, R. G. (2008) · Hepatology · doi:10.1002/hep.22193 · Cited by 1,059
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Lee, K. S., Buck, M., Houglum, K., & Chojkier, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118304 · Cited by 539
Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses
Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P. A., Modlin, R. L., Liblau, R. S., Gressner, A. M., & Kaufmann, S. H. E. (2007) · Immunity · doi:10.1016/j.immuni.2006.11.011 · Cited by 410
Lee, C. G., Cho, S. J., Kang, M. J., Chapoval, S. P., Lee, P. J., Noble, P. W., Yehualaeshet, T., Lu, B., Flavell, R. A., Milbrandt, J., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040104 · Cited by 369
Cited by
Items 301–400 of 889
Li, Y., Zhang, T., Zhang, J., Liu, Q., Jia, Q., Chen, W., Tang, Q., Xiong, Y., Xia, Y., Xu, Y., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122232 · Cited by 52
Liu, W., Zhang, L., Wei, X., Xu, Y., Fang, Q., Qi, S., Chen, J., Wang, C., Wang, S., Qin, L., et al. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121659 · Cited by 52
Osthole ameliorates hepatic fibrosis and inhibits hepatic stellate cell activation
Liu, Y.-W., Chiu, Y., Fu, S., & Huang, Y. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0168-5 · Cited by 52
Dai, W., Zhao, J., Tang, N., Zeng, X. Y., Wu, K., Ye, C., Shi, J. G., Lu, C., Ning, B., Zhang, J., et al. (2014) · Liver International · doi:10.1111/liv.12660 · Cited by 52
Origin of fibrosing cells in systemic sclerosis
Ebmeier, S., & Horsley, V. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000217 · Cited by 48
Resident mesenchymal cells and fibrosis
Hutchison, N., Fligny, C., & Duffield, J. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.015 · Cited by 51
“fate-mapped HSCs with Coll-Cre− and Coll-Cre mice, demonstrating that these cells go on to become the collagen-producingmyofibroblasts seen in liver fibrosis [18].”
BackgroundMolecular Cues Guiding Matrix Stiffness in Liver Fibrosis
Saneyasu, T., Akhtar, R., & Sakai, T. (2016) · BioMed Research International · doi:10.1155/2016/2646212 · Cited by 52
Reproducibility of shear wave elastography (SWE) in patients with chronic liver disease
Mancini, M., Megna, M., Ragucci, M., Luca, M. D., Marsilia, G. M., Nardone, G., Coccoli, P., Prinster, A., Mannelli, L., Vergara, E., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185391 · Cited by 51
Bobowski, M., Zummo, F. P., Staels, B., Lefèbvre, P., & Eeckhoute, J. (2018) · Cells · doi:10.3390/cells7090137 · Cited by 52
Li, H. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.07.006 · Cited by 51
Kong, D., Zhang, F., Zhang, Z., Lu, Y., & Zheng, S. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.10.002 · Cited by 51
Kuehl, T., & Lagares, D. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.020 · Cited by 50
Inactivation of myofibroblasts during regression of liver fibrosis
Kisseleva, T., & Brenner, D. A. (2013) · Cell Cycle · doi:10.4161/cc.23549 · Cited by 47
Self-citationTimperi, E., Croizer, H., Khantakova, D., Rana, M., Molgora, M., Guerriero, J. L., Mechta-Grigoriou, F., & Romano, E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1690 · Cited by 49
Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling.
Delire, B., Lebrun, V., Selvais, C., Henriet, P., Bertrand, A., Horsmans, Y., & Leclercq, I. A. (2016) · Aging · doi:10.18632/aging.101124 · Cited by 49
Paish, H. L., Kalson, N. S., Smith, G. R., del Carpio Pons, A., Baldock, T. E., Smith, N., Swist-Szulik, K., Weir, D. J., Bardgett, M., Deehan, D. J., et al. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.11.007 · Cited by 44
Granato, G., Ruocco, M. R., Iaccarino, A., Masone, S., Calì, G., Avagliano, A., Russo, V., Bellevicine, C., Spigna, G. D., Fiume, G., et al. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.38 · Cited by 49
Engineering the cellular mechanical microenvironment – from bulk mechanics to the nanoscale
Matellan, C., & Hernández, A. E. D. R. (2019) · Journal of Cell Science · doi:10.1242/jcs.229013 · Cited by 48
Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
Claveria-Cabello, A., Colyn, L., Arechederra, M., Urman, J. M., Berasain, C., Avila, M. A., & Fernandez-Barrena, M. G. (2020) · Cells · doi:10.3390/cells9102321 · Cited by 43
Pericytes in Chronic Lung Disease
Rowley, J. E., & Johnson, J. R. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000365051 · Cited by 43
Fetal liver development and implications for liver disease pathogenesis
Lotto, J., Stephan, T. L., & Hoodless, P. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00775-2 · Cited by 64
Liver cirrhosis: An overview of experimental models in rodents
Faccioli, L. A. P., Dias, M. L., Paranhos, B. A., & dos Santos Goldenberg, R. C. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120615 · Cited by 47
Cardiac fibroblasts in myocardial injury and heart failure
Linthout, S. V., Matz, I., González, A., & Davis, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf902 · Cited by 48
Modulation of retinoid signaling: therapeutic opportunities in organ fibrosis and repair
Wang, S., Yu, J., Kane, M. A., & Moise, A. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107415 · Cited by 47
Ceramide and Sphingosine 1-Phosphate in Liver Diseases.
Park, W., Song, J.-H., Kim, G., & Park, T. (2020) · PubMed Central · doi:10.14348/molcells.2020.0054 · Cited by 47
Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management
El-Fattah, E. E. A., & Zakaria, A. Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03759-z · Cited by 47
Determining the fate of hepatic cells by lineage tracing: Facts and pitfalls
Lemaigre, F. P. (2015) · Hepatology · doi:10.1002/hep.27659 · Cited by 42
Contribution of bone marrow-derived fibrocytes to liver fibrosis.
Xu, J., Cong, M., Park, T. J., Scholten, D., Brenner, D. A., & Kisseleva, T. (2015) · PubMed · doi:10.3978/j.issn.2304-3881.2015.01.01 · Cited by 37
Self-citationMehta, K. J., Coombes, J. D., Briones-Orta, M. A., Manka, P. P., Williams, R. L., Patel, V. B., & Syn, W. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.08.012 · Cited by 46
Circular RNA circPSD3 alleviates hepatic fibrogenesis by regulating the miR-92b-3p/Smad7 axis
Bu, F., Zhu, Y. Y., Chen, X., Wang, A., Zhang, Y., You, H., Yang, Y., Yang, Y., Huang, C., & Li, J. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.01.007 · Cited by 47
Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review
Khan, S., & Saxena, R. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000312 · Cited by 48
Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues
Dooling, L. J., Saini, K., Anlaş, A. A., & Discher, D. E. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.06.006 · Cited by 46
Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis
Li, X., Wu, X., Xu, T., Li, X., Yang, Y., Li, W., Huang, C., Meng, X., & Li, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.07.003 · Cited by 45
Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment
Talal, A. H., Venuto, C. S., & Younis, I. R. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.336 · Cited by 45
Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing
Vollmann, E. H., Cao, L., Amatucci, A., Reynolds, T. L., Hamann, S., Dalkilic-Liddle, I., Cameron, T. O., Hoßbach, M., Kauffman, K. J., Mir, F. F., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.014 · Cited by 44
Self-citationIredale, J. P., Pellicoro, A., & Fallowfield, J. A. (2017) · Digestive Diseases · doi:10.1159/000456581 · Cited by 44
Hypertrophic Scarring: Current Knowledge of Predisposing Factors, Cellular and Molecular Mechanisms
Nabai, L., Pourghadiri, A., & Ghahary, A. (2020) · Journal of Burn Care & Research · doi:10.1093/jbcr/irz158 · Cited by 44
Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
Yavuz, B. G., Pestana, R. C., Abugabal, Y. I., Krishnan, S., Chen, J., Hassan, M. M., Wolff, R. A., Rashid, A., Amin, H. M., & Kaseb, A. O. (2020) · Oncotarget · doi:10.18632/oncotarget.27532 · Cited by 45
Regression of portal hypertension: underlying mechanisms and therapeutic strategies
Selicean, S. E., Wang, C., Guixé‐Muntet, S., Ştefănescu, H., Kawada, N., & Gracia‐Sancho, J. (2021) · Hepatology International · doi:10.1007/s12072-021-10135-4 · Cited by 44
Janebodin, K., Buranaphatthana, W., Ieronimakis, N. M., Hays, A. L., & Reyes, M. (2013) · BioMed Research International · doi:10.1155/2013/815895 · Cited by 43
Healing scars: targeting pericytes to treat fibrosis
Greenhalgh, S. N., Conroy, K. P., & Henderson, N. C. (2015) · QJM · doi:10.1093/qjmed/hcu067 · Cited by 39
Inhibitory Effect of Tanshinone IIA on Rat Hepatic Stellate Cells
Liu, Y., & Huang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103229 · Cited by 44
Molecular determinants of mesenchymal cell activation in fibroproliferative diseases
Penke, L. R. K., & Peters-Golden, M. L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03212-3 · Cited by 44
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope
Hinchcliff, M., & O’Reilly, S. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00918-3 · Cited by 47
Cellular senescence in liver fibrosis: Implications for age-related chronic liver diseases
Udomsinprasert, W., Sobhonslidsuk, A., Jittikoon, J., Honsawek, S., & Chaikledkaew, U. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1992385 · Cited by 40
Space of Disse: a stem cell niche in the liver
Häussinger, D., & Kordes, C. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0283 · Cited by 43
Cardiac fibroblast diversity in health and disease
Soliman, H., & Rossi, F. M. V. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.05.003 · Cited by 39
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications
Geng, Y., & Schwabe, R. F. (2025) · Hepatology · doi:10.1097/hep.0000000000001386 · Cited by 41
Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis
Smirne, C., Rigamonti, C., Benedittis, C. D., Sainaghi, P. P., Bellan, M., Burlone, M. E., Castello, L. M., & Avanzi, G. C. (2019) · Disease Markers · doi:10.1155/2019/2304931 · Cited by 41
Yu, C., Yu, C., & Chang, Y. (2016) · Scientific Reports · doi:10.1038/srep37004 · Cited by 40
Sistare, F. D., Mattes, W. B., & LeCluyse, E. L. (2016) · ILAR Journal · doi:10.1093/ilar/ilw025 · Cited by 40
Kikuchi, A., Singh, S., Poddar, M., Nakao, T., Schmidt, H. M., Gayden, J. D., Sato, T., Arteel, G. E., & Monga, S. P. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.06.006 · Cited by 40
Nielsen, M. J., Karsdal, M. A., Kazankov, K., Grønbæk, H., Krag, A. A., Leeming, D. J., Schuppan, D., & George, J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13819 · Cited by 39
Rohn, F., Kordes, C., Buschmann, T., Reichert, D., Wammers, M., Poschmann, G., Stühler, K., Benk, A. S., Geiger, F., Spatz, J. P., et al. (2020) · Aging Cell · doi:10.1111/acel.13131 · Cited by 34
Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
Song, N., Xu, H., Liu, J., Zhao, Q., Chen, H., Yan, Z., Yang, R., Luo, Z., Liu, Q., Ouyang, J., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.016 · Cited by 39
p53 and Myofibroblast Apoptosis in Organ Fibrosis
McElhinney, K., Irnaten, M., & O'Brien, C. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076737 · Cited by 39
New therapies for hepatic fibrosis
Koyama, Y., & Brenner, D. A. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.06.011 · Cited by 37
Self-citationBone marrow-derived fibrocytes contribute to liver fibrosis
Xu, J., & Kisseleva, T. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215584933 · Cited by 37
Self-citationReversibility of Stricturing Crohnʼs Disease—Fact or Fiction?
Bettenworth, D., & Rieder, F. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000598 · Cited by 39
Sant’Anna, L. B., Hage, R., Cardoso, M. A. G., Arisawa, E. Â. L. S., Cruz, M. M., Parolini, O., Cargnoni, A., & Sant’Anna, N. (2016) · Cell Transplantation · doi:10.3727/096368916x692645 · Cited by 39
Qu, J., Chen, H., Zhu, L., Ambalavanan, N., Girkin, C. A., Murphy-Ullrich, J. E., Downs, J. C., & Zhou, Y. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17848 · Cited by 38
Epigenetic regulation of hepatic stellate cell activation and liver fibrosis
Taghdouini, A. E., & van Grunsven, L. A. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1251309 · Cited by 38
IL-17A in Human Liver: Significant Source of Inflammation and Trigger of Liver Fibrosis Initiation
Kartasheva-Ebertz, D., Gaston, J., Lair-Mehiri, L., Mottez, E., Buivan, T.-P., Massault, P. P., Scatton, O., Gaujoux, S., Vaillant, J., Pol, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179773 · Cited by 38
The Material World of 3D‐Bioprinted and Microfluidic‐Chip Models of Human Liver Fibrosis
Carvalho, A. M., Bansal, R., Barrias, C. C., & Sarmento, B. F. C. C. (2023) · Advanced Materials · doi:10.1002/adma.202307673 · Cited by 38
Abdelghany, A. H., Basalamah, M. A., Idris, S., Ahmad, J., & Refaat, B. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1040-4 · Cited by 38
Cre‐ativity in the liver: Transgenic approaches to targeting hepatic nonparenchymal cells
Greenhalgh, S. N., Conroy, K. P., & Henderson, N. C. (2015) · Hepatology · doi:10.1002/hep.27606 · Cited by 37
Reversion of hepatic stellate cell to a quiescent phenotype: From myth to reality?
Mallat, A., & Lotersztajn, S. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.031 · Cited by 30
Soluble Thy-1 reverses lung fibrosis via its integrin-binding motif
Tan, C., Jiang, M., Wong, S. S., Espinoza, C. R., Kim, C., Li, X., Connors, E. P., & Hagood, J. S. (2019) · JCI Insight · doi:10.1172/jci.insight.131152 · Cited by 36
Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics
Singh, S., Sharma, N., Shukla, S., Behl, T., Gupta, S., Anwer, M. K., Vargas-De-La-Cruz, C. B., BUNGAU, S. G., & Brisc, M. C. (2023) · Molecules · doi:10.3390/molecules28062811 · Cited by 37
Plant‐derived flavonoids are a potential source of drugs for the treatment of liver fibrosis
Zhao, B., Liu, K., Liu, X., Li, Q., Li, Z., Xi, J., Xie, F., & Li, X. (2024) · Phytotherapy Research · doi:10.1002/ptr.8193 · Cited by 36
Pro- and Anti-fibrogenic Functions of Gram-Negative Bacterial Lipopolysaccharide in the Liver
Gandhi, C. R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00130 · Cited by 36
Zhang, N., Yao, H., Zhang, Z., Li, Z., Chen, X., Zhao, Y., Ju, R., He, J., Pan, H., Liu, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131588 · Cited by 35
Saito, Y., Morine, Y., & Shimada, M. (2017) · Hepatology Research · doi:10.1111/hepr.12872 · Cited by 35
A survey of herbal medicines as tumor microenvironment‐modulating agents
Park, C., Lee, J., Son, C., & Lee, N. (2020) · Phytotherapy Research · doi:10.1002/ptr.6784 · Cited by 35
The role of hepatic microenvironment in hepatic fibrosis development
Meng, Y., Zhao, T., Zhang, Z., & Zhang, D. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2132418 · Cited by 37
Ackerman, J. E., Muscat, S. N., Adjei‐Sowah, E., Korcari, A., Nichols, A. E. C., Buckley, M. R., & Loiselle, A. E. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.12.004 · Cited by 37
Ge, J., Chang, N., Zhao, Z., Tian, L., Duan, X., Yang, L., & Li, L. (2016) · Scientific Reports · doi:10.1038/srep22141 · Cited by 35
Nrf2 activation is required for curcumin to induce lipocyte phenotype in hepatic stellate cells
Lu, C., Xu, W., & Zheng, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.037 · Cited by 35
Hải, N. T. T., Thủy, L. T. T., Shiota, A., Kadono, C., Daikoku, A., Hoang, D. V., Dat, N. Q., Sato-Matsubara, M., Yoshizato, K., & Kawada, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-36215-4 · Cited by 35
Isolation and Time Lapse Microscopy of Highly Pure Hepatic Stellate Cells
Bartneck, M., Warzecha, K. T., Tag, C. G., Sauer-Lehnen, S., Heymann, F., Trautwein, C., Weiskirchen, R., & Tacke, F. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/417023 · Cited by 34
Functional heterogeneity of resident fibroblasts in the kidney
Sato, Y., & Yanagita, M. (2019) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.95.033 · Cited by 34
Wang, Y., Fan, X., Lei, N., He, X., Wang, X., Luo, X., Zhang, D., & Pan, W. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00101 · Cited by 34
Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity
Yang, M. J., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011037 · Cited by 34
Ergosterol Is the Active Compound of Cultured Mycelium Cordyceps sinensis on Antiliver Fibrosis
Peng, Y., Tao, Y., Wang, Q., Shen, L., Yang, T., Liu, Z., & Liu, C. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/537234 · Cited by 34
Ma, H., Xu, J., Liu, X., Zhu, Y., Gao, B., Karin, M., Tsukamoto, H., Jeste, D. V., Grant, I., Roberts, A. J., et al. (2016) · Current Pathobiology Reports · doi:10.1007/s40139-016-0097-3 · Cited by 34
Self-citationInnovative Medicine: Basic Research and Development
Nakao, K., Minato, N., & Üemoto, S. (2015) · Springer eBooks · doi:10.1007/978-4-431-55651-0 · Cited by 10
Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice
Cong, M., Zhao, W., Liu, T., Wang, P., Fan, X., Zhai, Q., Bao, X., Zhang, D., You, H., Kisseleva, T., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3028 · Cited by 33
“Two-layer discontinuous density gradient centrifugation was performed as previously described (19).”
Self-citationTolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation
Hammad, S., Ogris, C., Othman, A., Erdoesi, P., Schmidt‐Heck, W., Biermayer, I., Helm, B., Gao, Y. L., Piorońska, W., Holland, C. H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05855-4 · Cited by 35
Yang, X., Tao, P., Zhang, K., Chen, L., Lv, J., Chen, Z., He, L., Jia, H., Sun, J. L., Cao, M., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02170-0 · Cited by 33
Myofibroblast‐Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model
Qu, C., He, L., Yao, N., Li, J., Jiang, Y., Li, B., Peng, S., Hu, K., Chen, D., Chen, G., et al. (2021) · Hepatology · doi:10.1002/hep.31754 · Cited by 33
Tang, M., Guo, C., Sun, M., Zhou, H., Peng, X., Dai, J., Ding, Q., Wang, Y., & Yang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.882243 · Cited by 34
Cheng, M., Li, J., Niu, X.-N., Zhu, L., Liu, J., Jia, P., Zhu, S., Meng, H., Lv, X., Huang, C., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115497 · Cited by 33
Matrix and cell phenotype differences in Dupuytren’s disease
van Beuge, M. M., ten Dam, E.-J. P. M., Werker, P. M. N., & Bank, R. A. (2016) · Fibrogenesis & Tissue Repair · doi:10.1186/s13069-016-0046-0 · Cited by 33
Zhang, H., Chen, F., Fan, X., Lin, C., Hao, Y., Wei, H., Lin, W., Jiang, Y., & He, F. (2017) · Scientific Reports · doi:10.1038/srep44910 · Cited by 33
The P2X4 purinergic receptor regulates hepatic myofibroblast activation during liver fibrogenesis
Guilcher, C. L., Garcin, I., Dellis, O., Cauchois, F., Tebbi, A., Doignon, I., Guettier, C., Julien, B., & Tordjmann, T. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.020 · Cited by 34
Hammad, S., Othman, A., Meyer, C., Telfah, A., Lambert, J., Dewidar, B., Werle, J., Nwosu, Z. C., Mahli, A., Dormann, C., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2254-4 · Cited by 33
Chen, J. Y., Newcomb, B., Zhou, C., Pondick, J. V., Ghoshal, S., York, S. R., Motola, D., Coant, N., Yi, J. K., Mao, C., et al. (2017) · Scientific Reports · doi:10.1038/srep44867 · Cited by 32
Lu, C., Xu, W., Shao, J., Zhang, F., Chen, A., & Zheng, S. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.06.001 · Cited by 34
Lao, Y., Li, Y., Zhang, P., Shao, Q., Lin, W., Qiu, B., Lv, Y., Tang, L., Su, S., Zhang, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.016 · Cited by 32
Wilson, C. L., Mann, J., Walsh, M., Perrugoria, M. J., Oakley, F., Wright, M. C., Brignole, C., Di Paolo, D., Perri, P., Ponzoni, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083391 · Cited by 31
“It is proposed that aHSC that avoid apoptosis during resolution of fibrogenesis can revert to a more quiescent phenotype (iHSC), although in a state where they are primed to activate more efficiently than naive qHSC [34,35].”
Metadata
- Authors
- Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., Evans, S. M., Dillmann, W., Glass, C. K., & Brenner, D. A.
- Affiliations
- Department of Medicine,
- Universitätsklinikum Aachen (DE)
- Department of Cellular and Molecular Medicine,
- School of Pharmacy, University of California, San Diego, CA 92093;
- University of Southern California (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-05-07
- Volume
- 109
- Issue
- 24
- Pages
- 9448-9453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3386114
- OpenAlex
- W2075290880
- Cited by
- 805
- References
- 27
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 61 · 2023: 59 · 2022: 53 · 2021: 62 · 2020: 64 · 2019: 52 · 2018: 53 · 2017: 61 · 2016: 64 · 2015: 73 · 2014: 63 · 2013: 42 · 2012: 13
- FWCI
- 38.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041804)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- myofibroblasts, hepatic stellate cells, liver fibrosis, fibrosis regression, apoptosis, anti-apoptotic genes, carbon tetrachloride, alcohol-induced liver injury, fibrogenic gene expression
- MeSH terms
- Animals, Liver Cirrhosis, Phenotype, Tamoxifen, Adoptive Transfer, Collagen Type I, Mice, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.